{"id":"cd19","name":"CD19","symbol":"CD19","route":"/targets/cd19/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1633","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177455","uniprot":"https://www.uniprot.org/uniprotkb/P15391/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P15391","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3390821","open-targets":"https://platform.opentargets.org/target/ENSG00000177455","civic":"https://civicdb.org/genes/930/summary","oncokb":"https://www.oncokb.org/gene/CD19","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD19","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CD19","depmap":"https://depmap.org/portal/gene/CD19?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000177455-CD19","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/930","omim":"https://www.omim.org/entry/107265"}],"products":[{"id":"at101","name":"AT101","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/at101/"},{"id":"axicabtagene-ciloleucel","name":"Axicabtagene ciloleucel","status":"approved","modality":"CAR-T (CD19)","route":"/drugs/axicabtagene-ciloleucel/"},{"id":"azd0120","name":"AZD0120","status":"phase-3","modality":"CAR-T cell therapy","route":"/drugs/azd0120/"},{"id":"azd0486","name":"AZD0486","status":"phase-3","modality":"bispecific antibody","route":"/drugs/azd0486/"},{"id":"blinatumomab","name":"Blinatumomab","status":"approved","modality":"Bispecific T-cell engager (CD19×CD3)","route":"/drugs/blinatumomab/"},{"id":"brexucabtagene-autoleucel","name":"Brexucabtagene autoleucel","status":"approved","modality":"Autologous CD19 CAR-T (CD28 costimulatory domain)","route":"/drugs/brexucabtagene-autoleucel/"},{"id":"cd19-t-hank","name":"CD19 t-haNK","status":"phase-2","modality":"cell therapy (type not stated)","route":"/drugs/cd19-t-hank/"},{"id":"crc01","name":"CRC01","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/crc01/"},{"id":"ctx112","name":"CTX112","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/ctx112/"},{"id":"englumafusp-alfa","name":"Englumafusp alfa","status":"phase-2","modality":"fusion protein","route":"/drugs/englumafusp-alfa/"},{"id":"gc012f","name":"GC012F","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/gc012f/"},{"id":"inaticabtagene-autoleucel","name":"Inaticabtagene autoleucel","status":"approved","modality":"Cell therapy (autologous CD19 CAR-T)","route":"/drugs/inaticabtagene-autoleucel/"},{"id":"jnj-90014496","name":"JNJ-90014496","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/jnj-90014496/"},{"id":"lisocabtagene-maraleucel","name":"Lisocabtagene maraleucel","status":"approved","modality":"CAR-T (CD19, defined CD4:CD8)","route":"/drugs/lisocabtagene-maraleucel/"},{"id":"zynlonta","name":"Loncastuximab tesirine","status":"approved","modality":"ADC","route":"/drugs/zynlonta/"},{"id":"mk-1045","name":"MK-1045","status":"phase-3","modality":"bispecific antibody (CD3 x CD19, per the sponsor's description; form not stated in the registry record)","route":"/drugs/mk-1045/"},{"id":"obecabtagene-autoleucel","name":"Obecabtagene autoleucel","status":"approved","modality":"CAR-T (CD19, fast off-rate)","route":"/drugs/obecabtagene-autoleucel/"},{"id":"relmacabtagene-autoleucel","name":"Relmacabtagene autoleucel","status":"approved","modality":"Cell therapy (autologous CD19 CAR-T, 4-1BB)","route":"/drugs/relmacabtagene-autoleucel/"},{"id":"rondecabtagene-autoleucel","name":"Rondecabtagene autoleucel","status":"phase-3","modality":"CAR-T cell therapy","route":"/drugs/rondecabtagene-autoleucel/"},{"id":"tafasitamab","name":"Tafasitamab","status":"approved","modality":"Monoclonal antibody (anti-CD19, Fc-enhanced)","route":"/drugs/tafasitamab/"},{"id":"talicabtagene-autoleucel","name":"Talicabtagene autoleucel","status":"approved","modality":"CAR-T (CD19, humanised)","route":"/drugs/talicabtagene-autoleucel/"},{"id":"tbi-1501","name":"TBI-1501","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/tbi-1501/"},{"id":"tc011","name":"TC011","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/tc011/"},{"id":"tisagenlecleucel","name":"Tisagenlecleucel","status":"approved","modality":"CAR-T (CD19)","route":"/drugs/tisagenlecleucel/"},{"id":"varnimcabtagene-autoleucel","name":"Varnimcabtagene autoleucel","status":"approved","modality":"CAR-T (CD19, academic origin)","route":"/drugs/varnimcabtagene-autoleucel/"},{"id":"zamtocabtagene-autoleucel","name":"Zamtocabtagene autoleucel","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/zamtocabtagene-autoleucel/"}],"trials":[{"id":"nct04680052","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa","nct":"NCT04680052","phase":"3","status":"active"},{"id":"frontmind","name":"frontMIND","nct":"NCT04824092","phase":"3","status":"positive"},{"id":"aall1731","name":"COG AALL1731","nct":"NCT03914625","phase":"3","status":"positive"},{"id":"e1910","name":"ECOG-ACRIN E1910","nct":"NCT02003222","phase":"3","status":"positive"},{"id":"transform","name":"TRANSFORM","nct":"NCT03575351","phase":"3","status":"positive"},{"id":"aall1331","name":"AALL1331","nct":"NCT02101853","phase":"3","status":"mixed"},{"id":"zuma-7","name":"ZUMA-7","nct":"NCT03391466","phase":"3","status":"positive"},{"id":"interfant-06","name":"Interfant-06","nct":"NCT00550992","phase":"3","status":"mixed"},{"id":"tower","name":"TOWER","nct":"NCT02013167","phase":"3","status":"positive"},{"id":"nct05888493","name":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","nct":"NCT05888493","phase":"3","status":"active"},{"id":"nct06549595","name":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","nct":"NCT06549595","phase":"3","status":"recruiting"},{"id":"nct07188558","name":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","nct":"NCT07188558","phase":"3","status":"recruiting"},{"id":"nct07215585","name":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","nct":"NCT07215585","phase":"3","status":"recruiting"},{"id":"intreall-sr-2010","name":"IntReALL SR 2010","nct":"NCT01802814","phase":"3","status":"completed"},{"id":"nct05371093","name":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","nct":"NCT05371093","phase":"3","status":"active"},{"id":"nct04094311","name":"Study of Out of Specification for Tisagenlecleucel","nct":"NCT04094311","phase":"3","status":"recruiting"},{"id":"nct04384484","name":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lym","nct":"NCT04384484","phase":"3","status":"active"},{"id":"nct05429268","name":"Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (","nct":"NCT05429268","phase":"3","status":"active"},{"id":"nct07509151","name":"Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He","nct":"NCT07509151","phase":"3","status":"recruiting"},{"id":"nct07634471","name":"A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)","nct":"NCT07634471","phase":"2/3","status":"recruiting"},{"id":"nct07570173","name":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","nct":"NCT07570173","phase":"2/3","status":"recruiting"},{"id":"imagine-varnimcabtagene","name":"IMAGINE (varnimcabtagene autoleucel, Immuneel)","phase":"2","status":"positive"},{"id":"elara","name":"ELARA","nct":"NCT03568461","phase":"2","status":"positive"},{"id":"lotis-2","name":"LOTIS-2","nct":"NCT03589469","phase":"2","status":"positive"},{"id":"reliance","name":"RELIANCE","phase":"2","status":"positive"},{"id":"zuma-5","name":"ZUMA-5","nct":"NCT03105336","phase":"2","status":"positive"},{"id":"d-alba","name":"D-ALBA (GIMEMA LAL2116)","nct":"NCT02744768","phase":"2","status":"positive"},{"id":"l-mind","name":"L-MIND","nct":"NCT02399085","phase":"2","status":"positive"},{"id":"zuma-2","name":"ZUMA-2","nct":"NCT02601313","phase":"2","status":"positive"},{"id":"juliet","name":"JULIET","nct":"NCT02445248","phase":"2","status":"positive"},{"id":"eliana","name":"ELIANA","nct":"NCT02435849","phase":"2","status":"positive"},{"id":"nct07015242","name":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","nct":"NCT07015242","phase":"2","status":"recruiting"},{"id":"nct06179524","name":"CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL","nct":"NCT06179524","phase":"2","status":"recruiting"},{"id":"nct06479356","name":"CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma","nct":"NCT06479356","phase":"2","status":"recruiting"},{"id":"nct04684147","name":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","nct":"NCT04684147","phase":"2","status":"recruiting"},{"id":"nct07288879","name":"DALY II Japan/MB-CART2019.1 for DLBCL","nct":"NCT07288879","phase":"2","status":"recruiting"},{"id":"nct04792489","name":"DALY II USA/ MB-CART2019.1 for DLBCL","nct":"NCT04792489","phase":"2","status":"recruiting"},{"id":"nct04844866","name":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","nct":"NCT04844866","phase":"2","status":"recruiting"},{"id":"nct06550141","name":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","nct":"NCT06550141","phase":"2","status":"recruiting"},{"id":"nct06465433","name":"Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab","nct":"NCT06465433","phase":"2","status":"recruiting"},{"id":"nct04586478","name":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","nct":"NCT04586478","phase":"2","status":"recruiting"},{"id":"nct06093841","name":"Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL","nct":"NCT06093841","phase":"2","status":"active"},{"id":"nct06508931","name":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms","nct":"NCT06508931","phase":"2","status":"recruiting"},{"id":"nct03876769","name":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","nct":"NCT03876769","phase":"2","status":"active"},{"id":"nct06253663","name":"Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L","nct":"NCT06253663","phase":"2","status":"active"},{"id":"nct07125872","name":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","nct":"NCT07125872","phase":"2","status":"recruiting"},{"id":"nct06526793","name":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","nct":"NCT06526793","phase":"2","status":"recruiting"},{"id":"nct05222555","name":"Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients","nct":"NCT05222555","phase":"1/2","status":"active"},{"id":"talicel-phase-1-2","name":"Talicabtagene autoleucel (NexCAR19) phase 1/2","phase":"1/2","status":"positive"},{"id":"felix","name":"FELIX","nct":"NCT04404660","phase":"1/2","status":"positive"},{"id":"transcend-cll-004","name":"TRANSCEND CLL 004","nct":"NCT03331198","phase":"1/2","status":"positive"},{"id":"zuma-1","name":"ZUMA-1","nct":"NCT02348216","phase":"1/2","status":"positive"},{"id":"nct05579132","name":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)","nct":"NCT05579132","phase":"1/2","status":"recruiting"},{"id":"nct07519772","name":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","nct":"NCT07519772","phase":"1/2","status":"recruiting"},{"id":"nct05643742","name":"A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies","nct":"NCT05643742","phase":"1/2","status":"recruiting"},{"id":"nct03930953","name":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No","nct":"NCT03930953","phase":"1/2","status":"active"},{"id":"nct06564038","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","nct":"NCT06564038","phase":"1/2","status":"recruiting"},{"id":"nct05667506","name":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","nct":"NCT05667506","phase":"1/2","status":"recruiting"},{"id":"nct06235229","name":"A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma","nct":"NCT06235229","phase":"1/2","status":"recruiting"},{"id":"nct05421663","name":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","nct":"NCT05421663","phase":"1/2","status":"active"},{"id":"nct05658562","name":"A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL","nct":"NCT05658562","phase":"1/2","status":"active"},{"id":"nct04521231","name":"A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL","nct":"NCT04521231","phase":"1/2","status":"active"},{"id":"nct07134088","name":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","nct":"NCT07134088","phase":"1/2","status":"active"},{"id":"nct04077723","name":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi","nct":"NCT04077723","phase":"1/2","status":"active"},{"id":"nct05850234","name":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","nct":"NCT05850234","phase":"1/2","status":"recruiting"},{"id":"nct06948981","name":"GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies","nct":"NCT06948981","phase":"1/2","status":"recruiting"},{"id":"nct05326243","name":"Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma","nct":"NCT05326243","phase":"1/2","status":"recruiting"},{"id":"nct07387926","name":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","nct":"NCT07387926","phase":"1/2","status":"recruiting"},{"id":"nct05338931","name":"Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","nct":"NCT05338931","phase":"1/2","status":"recruiting"},{"id":"nct07284433","name":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","nct":"NCT07284433","phase":"1/2","status":"recruiting"},{"id":"nct04836507","name":"Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients","nct":"NCT04836507","phase":"1/2","status":"recruiting"},{"id":"nct05826535","name":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","nct":"NCT05826535","phase":"1/2","status":"recruiting"},{"id":"nct07473167","name":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","nct":"NCT07473167","phase":"1/2","status":"recruiting"},{"id":"nct03155191","name":"Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia","nct":"NCT03155191","phase":"1/2","status":"active"},{"id":"nct04661007","name":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL","nct":"NCT04661007","phase":"1/2","status":"active"},{"id":"transcend-nhl-001","name":"TRANSCEND NHL 001","nct":"NCT02631044","phase":"1","status":"positive"}],"pathways":["resistance-routes-map","t-cell-exhaustion"],"companies":["abclon","adc-therapeutics","allogene","amgen","astrazeneca","autolus","bms","capstan-therapeutics","caribou","cellogen","century-therapeutics","cipla","crispr-therapeutics","cullinan-therapeutics","fate-therapeutics","gilead","gracell-biotechnologies","iksuda-therapeutics","immuneel","immunitybio","immunoact","imugene","incyte","janux-therapeutics","johnson-johnson","juventas-cell-therapy","jw-therapeutics","kelonia-therapeutics","kernal-biologics","lyell-immunopharma","merck","miltenyi-biomedicine","morphosys","nkarta","novartis","orna-therapeutics","poseida-therapeutics","roche-genentech","sana-biotechnology","takara-bio","umoja-biopharma","wuxi-apptec"],"keyPapers":["paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026","paper-aall1731-blinatumomab-children-nejm-2025","paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","paper-zuma-5-axi-cel-indolent-lymphoma-lancet-oncol-2022","paper-belinda-tisagenlecleucel-second-line-nejm-2022","paper-elara-tisagenlecleucel-follicular-nat-med-2022","paper-transform-liso-cel-lancet-2022","paper-zuma-7-axi-cel-second-line-nejm-2022","paper-transcend-nhl-001-liso-cel-lancet-2020","paper-ucart19-allogeneic-car-t-lancet-2020","paper-zuma-2-brexu-cel-mantle-cell-nejm-2020","paper-juliet-tisagenlecleucel-dlbcl-nejm-2019","paper-eliana-tisagenlecleucel-nejm-2018","paper-zuma-1-axi-cel-nejm-2017","paper-maude-ctl019-all-nejm-2014","paper-gross-eshhar-chimeric-receptor-pnas-1989"],"hotspots":[],"openQuestions":[{"id":"cd19-in-vivo","question":"Can in vivo CAR-T (lentiviral or mRNA delivery of the CAR to the patient's own T cells) match ex vivo products in B-cell malignancies?","stage":"translational","actor":"industry","source":{"label":"ZUMA-1, NEJM 2017","url":"https://doi.org/10.1056/NEJMoa1707447"}}],"assays":[],"resistance":[{"class":"cd19-car-t","mechanism":"CD19-negative relapse","category":"antigen"},{"class":"cd19-car-t","mechanism":"CD19-positive relapse from poor CAR-T persistence","category":"pharmacology"},{"class":"cd19-car-t","mechanism":"Immunosuppressive microenvironment and T-cell exhaustion","category":"immune-evasion"},{"class":"anti-cd20","mechanism":"Loss or down-regulation of CD20","category":"antigen"},{"class":"cd3-bispecific","mechanism":"Loss of the tumour-side antigen","category":"antigen"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}